JP Morgan lifts Regeneron Pharma price target to $1050 a share
JP Morgan raised its Regeneron Pharma price target to $1050 from $950 and kept an Overweight rating. Dow Jones Newswires reported the change.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
JP Morgan analysts raised their price target on Regeneron Pharma shares to $1050 from $950. The bank kept its Overweight rating, meaning a recommendation to hold the stock above the market average.
Dow Jones Newswires reported the change, citing ratings data from Benzinga.
why it matters
A price target change of this kind concerns a single company and usually affects only its shares, so its relevance for the broad market is limited. The target reflects the analysts' valuation and is not a forecast of where the stock will trade.
tags
instruments
sources
- Regeneron Pharma Price Target Raised to $1050.00/Share From $950.00 by JP Morgan — Dow Jones Newswires, 31 October 2026 at 00:28 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗